^
Association details:
| Biomarker: | CD19 positive |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | A-319 (CD3 agonist, CD19 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Safety and Efficacy of a-319 (a CD3xCD19 T cell engager) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Published date:
11/02/2023
Excerpt:
A total of 21 B-NHL patients (CD19+) were treated with A-319 for at least 1 cycle….In the 5 th cohort (at the dose level of 1.2 ug/kg/day), one patient with diffuse large B cell lymphoma (DLBCL) achieved CR, one with follicular lymphoma (FL) achieved PR...
DOI:
https://doi.org/10.1182/blood-2023-188071
